This inventor holds 2 USPTO granted patents. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2019-2022.
Company Filing History:
Years Active: 2019-2022
Title: David Robert Rainey: Innovator in Biomarker Research
Introduction
David Robert Rainey is a notable inventor based in Slough, GB. He has made significant contributions to the field of biomarker research, particularly in relation to IL-17 mediated diseases. With a total of 2 patents, his work has the potential to impact therapeutic strategies for various medical conditions.
Latest Patents
Rainey's latest patents focus on the use of lipocalin 2 (LCN2) as a biomarker for IL-17 inhibitor therapy efficacy. The first patent outlines the application of lipocalin 2 in monitoring the response of patients to anti-IL-17 therapy. This innovative approach aims to enhance the understanding of treatment effectiveness in IL-17 mediated diseases.
Career Highlights
Throughout his career, David Robert Rainey has worked with prominent companies such as UCB Biopharma Sprl and UCB Biopharma Srl. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Adam Samuel Platt and Stephen Edward Rapecki. Their collaborative efforts have further advanced the research and development of biomarkers in therapeutic applications.
Conclusion
David Robert Rainey is a distinguished inventor whose work in biomarker research is paving the way for improved therapies in IL-17 mediated diseases. His contributions are invaluable to the medical community and hold promise for future advancements in treatment efficacy.